公开(公告)号：US20210238143A1

公开(公告)日：2021-08-05

申请号：US17049680

申请日：2019-04-19

申请人： INSTITUTE NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) ,  UNIVERSITE DE RENNES 1 ,  CENTRE HOSPITALIER UNIVERSITAIRE DE BORDEAUX ,  INSTITUT BERGONIE ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) ,  UNIVERSITE DE BORDEAUX

发明人： Pierre VACHER ,  Patrick LEGEMBRE ,  Mickael JEAN ,  Patrick BLANCO ,  Pierre VAN DE WEGHE

IPC分类号： C07D233/64 ,  A61K45/06 ,  A61P37/00

摘要： The present invention relates the field of reducing CD95-mediated cell motility in a subject, in particular for their use in the reduction of CD-95 mediated cancer cell motility, the reduction of CD95-mediated lymphocyte motility and/or B cell maturation, or the treatment of B-cell tumors, in a subject. The inventors identified a novel family of compounds having the ability to disrupt CD95/PLCγ1 interaction and to neutralize the CD95-mediated calcium signaling pathway and cell migration in human peripheral blood lymphocytes (PBLs) and Th17 cells. Thus, the present invention relates to compounds of formula (A) as defined in the present text, to a pharmaceutical composition comprising said compounds in a pharmaceutically acceptable medium and to the use of these compounds and compositions as medicament, in particular for their use in the reduction or treatment of the above-mentioned pathologies, and in particular in the treatment of cancers and autoimmune inflammatory disease such as systemic lupus erythematosus, inflammatory condition and Th17-mediated disease.

公开(公告)号：US20180298104A1

公开(公告)日：2018-10-18

申请号：US15568205

申请日：2016-04-21

申请人： INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) ,  UNIVERSITY OF NOTTINGHAM ,  UNIVERSITE DE BORDEAUX ,  CHU HOPITAUX DE BORDEAUX ,  UNIVERSITE DE RENNES ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE(CNRS)

发明人： Patrick LEGEMBRE ,  Patrick BLANCO ,  Robin FLYNN

IPC分类号： C07K16/28 ,  C12N15/115 ,  C12N15/113

摘要： The present invention relates to methods and pharmaceutical compositions for the treatment of Th17-mediated diseases. In particular, the present invention relates to a method of treating a Th17-mediated disease in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a CD95 antagonist.

公开(公告)号：US20190350907A1

公开(公告)日：2019-11-21

申请号：US16478520

申请日：2018-01-15

申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) ,  UNIVERSITÉ DE RENNES 1 ,  UNIVERSITÉ DE BORDEAUX ,  INSTITUT BERGONIÉ ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) ,  CHU DE BORDEAUX

发明人： Patrick LEGEMBRE ,  Pierre VACHER ,  Amanda POISSONNIER ,  Patrick BLANCO

IPC分类号： A61K31/427 ,  A61K31/603 ,  A61K31/085 ,  A61K31/4439 ,  A61K31/704

摘要： The present invention relates to a method for reducing CD95-mediated cell motility. To identify chemicals disrupting CD95/PLCγ1 interaction, the inventors screened a chemical library of EMA/FDA-approved molecules against a protein-fragment complementation assay (PCA) monitoring the binding of CD95 to PLCγ1. From this screen, five chemical molecules showed the ability to disrupt CD95/PLCγ1 interaction and to neutralize the CD95-mediated calcium signaling pathway and cell migration in human peripheral blood lymphocytes (PBLs) and Th17 cells. Thus, the present invention relates to a method for reducing CD95-mediated cell motility, comprising administering the subject with at least one compound selected from the group consisting of HIV-protease inhibitors (e.g. ritonavir), diflunisal, anethole, rosiglitazone and daunorubicin. Particularly, the method of the invention find use in the treatment of cancer such as triple negative breast cancer, autoimmune inflammatory disease such as systemic lupus erythematosus, inflammatory condition and Th17-mediated disease.

公开(公告)号：US20190015397A1

公开(公告)日：2019-01-17

申请号：US16065932

申请日：2017-01-19

申请人： UNIVERSITÉ DE BORDEAUX ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  CENTRE HOSPITALIER UNIVERSITAIRE DE BORDEAUX

发明人： Marie-Élise TRUCHETET ,  Cécile CONTIN-BORDES ,  Patrick BLANCO ,  Thierry SCHAEVERBEKE ,  Thomas BARNETCHE

IPC分类号： A61K31/4365 ,  C07K16/28 ,  A61P37/06

摘要： Some embodiments are directed to a substance that inhibits P2Y12 receptor for use in the preventive treatment of systemic sclerosis in patients with Raynaud's phenomenon and a dysimmunity.